How The Cannabis Industry Can Learn From Psychedelics

Read original PsychedelicHealth article here

“Psilocybin products may be unregulated and even illegal in many markets, but producers of psilocybin are more conscious of the consumer than the cannabinoid industry appears to be.”

The CBD industry is promising and has potential for massive global growth; however, it can learn a few lessons from a much younger product industry; magic mushrooms.

The new industry of psychedelics has learned to use the cultural positives of magic mushrooms whilst simultaneously adopting the language of the regulatory regime that will one day administer it in a way that the THC and CBD market have failed to grasp.

While cannabinoid brands have been busy trying to compete in a grey market that is yet to exist, failing to establish a reliable product efficiency required for regulators to feel comfortable, psilocybin producers are focusing on user experience by providing dosing information, sourcing information and recommended use.

Though psilocybin products are largely unregulated and even illegal in many markets, the producers of psilocybin are more conscious of the consumer than the cannabinoid industry appears to be, currently drawing the attention of global investment and research very much in the same way the early cannabis industry did.

It would be a mistake to look on psilocybin products as naive just because they are newer. In the race to get investors, psilocybin is ahead of cannabis.